桦木三萜在遗传性大疱性表皮松解症中的临床应用

doi:10.12372/jcp.2026.25e1597

摘要/Abstract

摘要：

遗传性大疱性表皮松解症（EB）是一组由于遗传缺陷造成皮肤、黏膜机械脆性增高的遗传性皮肤病，可伴有营养不良、慢性炎症、感染、鳞状细胞癌等全身并发症，尚无治愈性疗法。桦木三萜是一种以桦木醇为主要活性成分的创新植物凝胶制剂，可通过调节创面炎症反应、促进角质形成细胞迁移及稳定真皮-表皮黏附力，加速创面愈合。此外，在减少操作疼痛、减少换药负担、减轻伤口负担包括伤口疼痛和瘙痒等方面也显示出积极作用，且总体安全性良好。本文对桦木三萜凝胶的作用机制、临床有效性、安全性及临床应用情况进行了综述，以期为中国EB患者的临床治疗提供参考依据。

关键词: 遗传性大疱性表皮松解症, 桦木三萜, 创面愈合, 有效性, 安全性

Abstract:

Epidermolysis bullosa (EB) is a group of inherited skin disorders caused by genetic defects that lead to increased mechanical fragility of the skin and mucous membranes. It can be accompanied by systemic complications such as malnutrition, chronic inflammation, infection, and squamous cell carcinoma. There is no curative treatment available. Birch triterpenes gel is an innovative botanical gel formulation primarily composed of betulin as the active ingredient. It accelerates wound healing by modulating the inflammatory response at the wound site, promoting keratinocyte migration, and stabilizing dermal-epidermal adhesion. Furthermore, it has demonstrated multiple positive outcomes in reducing procedural pain, decreasing the burden of dressing changes, and alleviating overall wound burden, including wound pain and itching, with an overall favorable safety profile. This article provides a review of the mechanism of action, clinical efficacy, safety, and clinical application of birch triterpenes gel, aiming to offer evidence-based guidance for the clinical management of EB patients in China.

Key words: epidermolysis bullosa, birch triterpenes, wound healing, efficacy, safety

中图分类号:

陈付英, 卢文敏, 李明. 桦木三萜在遗传性大疱性表皮松解症中的临床应用[J]. 临床儿科杂志, 2026, 44(5): 465-470.

CHEN Fuying, LU Wenmin, LI Ming. Clinical application of birch triterpenes extract in epidermolysis bullosa[J]. Journal of Clinical Pediatrics, 2026, 44(5): 465-470.

参考文献 31

[1]	Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility[J]. Br J Dermatol, 2020, 183(4): 614-627. doi: 10.1111/bjd.v183.4
[2]	Khanna D, Bardhan A. Epidermolysis Bullosa. In: StatPearls[EB/OL]. Treasure Island (FL): StatPearls Publishing; 2025 [2023-11-21]. https://www.ncbi.nlm.nih.gov/books/NBK470362.
[3]	Bardhan A, Bruckner-Tuderman L, Chapple ILC, et al. Epidermolysis bullosa[J]. Nat Rev Dis Primers, 2020, 6(1): 78. doi: 10.1038/s41572-020-0210-0 pmid: 32973163
[4]	刘子源, 申云, 董铭菲, 等. 大疱性表皮松解症的遗传学和治疗方法研究进展[J]. 生命科学, 2024, 36(2): 212-225.
	Liu ZY, Shen Y, Dong MF, et al. Research progress in genetics and treatment methods of epidermolysis bullosa[J]. Shengming Kexue, 2024, 36(2): 212-225.
[5]	Mellerio JE, Kiritsi D, Marinkovich MP, et al. Mapping the burden of severe forms of epidermolysis bullosa: implications for patient management[J]. JAAD Int, 2023, 11: 224-232. doi: 10.1016/j.jdin.2023.02.016
[6]	Bruckner AL, Losow M, Wisk J, et al. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers[J]. Orphanet J Rare Dis, 2020, 15(1): 1. doi: 10.1186/s13023-019-1279-y pmid: 31900176
[7]	Danescu S, Negrutiu M, Has C. Treatment of epidermolysis bullosa and future directions: a review[J]. Dermatol Ther (Heidelb), 2024, 14(8): 2059-2075. doi: 10.1007/s13555-024-01227-8
[8]	中华人民共和国国家卫生健康委员会. 罕见病诊疗指南(2019年版) [EB/OL]. (2019-02-27) [2025-08-11]. https://www.nhc.gov.cn/yzygj/c100068/201902/073540e8f83b4a54a28684d23e2ae2f5/files/1732871139221_41526.pdf.
	National Health Commission of the People's Republic of China. Guidelines for the Diagnosis and Treatment of Rare Diseases (2019 Edition)[EB/OL]. (2019-02-27) [2025-08-11]. https://www.nhc.gov.cn/yzygj/c100068/201902/073540e8f83b4a54a28684d23e2ae2f5/files/1732871139221_41526.pdf.
[9]	蝴蝶宝贝关爱中心. [EB/OL]. [2025-08-11]. https://www.debra.org.cn.
	Debra China. [EB/OL]. [2025-08-11]. https://www.debra.org.cn.
[10]	Fine JD, Johnson LB, Weiner M, et al. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006 [J]. J Am Acad Dermatol, 2009, 60(2): 203-211. doi: 10.1016/j.jaad.2008.09.035 pmid: 19026465
[11]	Pfendner EG, Lucky AW. Junctional Epidermolysis Bullosa[EB/M]. [2018-12-20]. GeneReviews. Seattle (WA): University of Washington, Seattle; 1993-2025. 2008.
[12]	Chen F, Wei R, Deng D, et al. Genotype and phenotype correlations in 441 patients with epidermolysis bullosa from China[J]. J Eur Acad Dermatol Venereol, 2023, 37(2): 411-419. doi: 10.1111/jdv.v37.2
[13]	Chen F, Huang L, Li C, et al. Next-generation sequencing through multigene panel testing for the diagnosis of hereditary epidermolysis bullosa in Chinese population[J]. Clin Genet, 2020, 98(2): 179-184. doi: 10.1111/cge.13791 pmid: 32484238
[14]	EB Research Network. What is EB? [EB/OL]. 2025-08-11 [2025-08-11]. https://www.eb-researchnetwork.org/research/what-is-eb.
[15]	陈劼, 吕军, 周迎春, 等. 遗传性大疱性表皮松解症367例问卷调查[J]. 中华皮肤科杂志, 2020, 53(2): 136-138.
	Chen J, Lyu J, Zhou YC, et al. A questionnaire survey of 367 patients with inherited epidermolysis bullosa[J]. Zhonghua Pifuke Zazhi, 2020, 53(2): 136-138.
[16]	Tang JY, Marinkovich MP, Lucas E, et al. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa[J]. Orphanet J Rare Dis, 2021, 16(1): 175. doi: 10.1186/s13023-021-01811-7 pmid: 33849616
[17]	Eng VA, Solis DC, Gorell ES, et al. Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey[J]. J Am Acad Dermatol, 2021, 85(5): 1161-1167. doi: 10.1016/j.jaad.2020.03.028 pmid: 32199895
[18]	Teng C, Solis D, Tang J, et al. Natural history of wounds in patients with recessive dystrophic epidermolysis bullosa[J]. Investig Dermatol, 2019, 139(5): S43.
[19]	Montaudie H, Chiaverini C, Sbidian E, et al. Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases[J]. Orphanet J Rare Dis, 2016, 11(1): 117. doi: 10.1186/s13023-016-0489-9 pmid: 27544590
[20]	Kim M, Li M, Intong-Wheeler L, et al. Epidemiology and outcome of squamous cell carcinoma in epidermolysis bullosa in Australia and New Zealand[J]. Acta Derm Venereol, 2018, 98(1): 70-76. doi: 10.2340/00015555-2781
[21]	Kern JS, Schwieger-Briel A, Lowe S, et al. Oleogel-S10 Phase 3 study "EASE" for epidermolysis bullosa: study design and rationale[J]. Trials, 2019, 20(1): 350. doi: 10.1186/s13063-019-3362-z pmid: 31186047
[22]	Schwieger-Briel A, Chakkittakandiyil A, Lara-Corrales I, et al. Instrument for scoring clinical outcome of research for epidermolysis bullosa: a consensus-generated clinical research tool[J]. Pediatr Dermatol, 2015, 32(1): 41-52. doi: 10.1111/pde.12317 pmid: 24650374
[23]	Scottish Medicines Consortium. Birch bark extract gel (Filsuvez®): Advice under the ultra-orphan framework[EB/OL]. (2024-07-08)[2025-08-11]. https://www.scottishmedicines.org.uk/medicines-advice/birch-bark-extract-filsuvez.
[24]	Jeon IK, On HR, Kim SC. Quality of Life and Economic Burden in Recessive Dystrophic Epidermolysis Bullosa[J]. Ann Dermatol, 2016, 28(1): 6-14. doi: 10.5021/ad.2016.28.1.6 pmid: 26848213
[25]	Goldschneider KR, Good J, Harrop E, et al. Pain care for patients with epidermolysis bullosa: best care practice guidelines[J]. BMC Med, 2014, 12: 178. doi: 10.1186/s12916-014-0178-2 pmid: 25603875
[26]	Shayegan LH, Levin LE, Galligan ER, et al. Skin cleansing and topical product use in patients with epidermolysis bullosa: Results from a multicenter database[J]. Pediatr Dermatol, 2020, 37(2): 326-332. doi: 10.1111/pde.14102 pmid: 31944391
[27]	Kern JS, Sprecher E, Fernandez MF, et al. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study[J]. Br J Dermatol, 2023, 188(1): 12-21. doi: 10.1093/bjd/ljac001 pmid: 36689495
[28]	Murrell DF, Bodemer C, Bruckner AL, et al. Long-term safety and efficacy of Oleogel-S10 (birch bark extract) in epidermolysis bullosa: 24-month results from the phase III EASE study[J]. Br J Dermatol, 2025, 192(6): 1007-1017. doi: 10.1093/bjd/ljaf022 pmid: 39821055
[29]	Bruckner A, Kiritsi D, Murrell D, et al. Oleogel-S10 reduces dressing changes burden and associated costs in patients with epidermolysis bullosa[J]. J Invest Dermatol, 2025, 145(3): e30.
[30]	Bruckner A, Kiritsi D, Murrell D. 274 Oleogel-S10 reduces dressing changes burden and associated costs in patients with epidermolysis bullosa[J]. J Investig Dermatol, 2024: 144S47.
[31]	Torres Pradilla M, Alvarez E, Novoa M, et al. OleogelS10 in dystrophic epidermolysis bullosa: a case series evaluating the impact on wound burden over two years[J]. Adv Ther, 2024, 41(2): 867-877. doi: 10.1007/s12325-023-02749-x